FTC Orders Illumina to Divest Cancer Detection Test Maker Grail

The US Federal Trade Commission on Monday ordered Illumina to divest cancer diagnostic test maker Grail, finding that its ownership would stifle competition in the US market for cancer tests.

Related Keywords

United States ,Washington ,Brussels ,Bruxelles Capitale ,Belgium ,Christine Wilson ,Diane Bartz ,Carl Icahn ,Svea Herbst ,Michael Chappell ,Us Federal Trade Commission ,European Union ,Trade Commission ,Bill Berkrot ,Genomics Genomic Medicine ,Cancer Diagnostics ,Antitrust ,Competition Law ,Dna Sequencing ,Dna Sequence ,Rna Sequences ,Sequencing Dna ,Next Generation Sequencing ,Bags ,Sequencing By Synthesis ,Jobs ,Whole Genome Sequencing ,Hromatin Immunoprecipitation Assays And Sequencing ,Hip Sequencing ,Hip Seq ,Microbial Sequencing ,